Eugene Kelleher

Discovery of 3-(3-(4-(1-Aminocyclobutyl)phenyl)-5-phenyl-3<i>H</i>-imidazo[4,5-<i>b</i>]pyridin-2-yl)pyridin-2-amine (ARQ 092): An Orally Bioavailable, Selective, and Potent Allosteric AKT Inhibitor

Jean‐Marc Lapierre, Sudharshan Eathiraj, David Vensel et al. · Journal of Medicinal Chemistry · 2016 · 111 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Discovery and Optimization of a STING Agonist Platform for Application in Antibody Drug Conjugates

Jeremy R. Duvall, Joshua D. Thomas, Raghida A. Bukhalid et al. · Journal of Medicinal Chemistry · 2023 · 52 citations · Full text

Pharmacy, Medicinal Chemistry, Oncology +17

XMT-2056, a HER2-Directed STING Agonist Antibody–Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells

Raghida A. Bukhalid, Jeremy R. Duvall, Kelly L. Lancaster et al. · Clinical Cancer Research · 2025 · 36 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Abstract 6706: Systemic administration of STING agonist antibody-drug conjugates elicit potent anti-tumor immune responses with minimal induction of circulating cytokines

Raghida A. Bukhalid, Jeremy R. Duvall, Naniye Mallı Cetinbas et al. · Cancer Research · 2020 · 25 citations

Pharmacy, Immunology, Oncology +16

Abstract 1738: XMT-2056, a well-tolerated, Immunosynthen-based STING-agonist antibody-drug conjugate which induces anti-tumor immune activity

Jeremy R. Duvall, Raghida A. Bukhalid, Naniye Mallı Cetinbas et al. · Cancer Research · 2021 · 24 citations

Pharmacy, Oncology, Pharmacology +17